ORMP
ORAMED PHARMACEUTICALS INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 1 ▼ 2 insiders sell $942.2K at $4.48
- Oct 1 ▼ 2 insiders sell $225.5K at $4.51
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $1.2M.
- InstitutionsBULLISH
Q3 2026: 14 added (0 new), 5 trimmed or exited.
- Short sellersSTEADY
Short interest −7.4% to 1.34M shares. 11.3 days to cover, ≈3.2% of shares.
- TrendDOWNTREND
10% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $2.2M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.4M |
| STRS OHIO | ADD | $880.3K |
| MORGAN STANLEY | DOUBLED | $504.3K |
| UBS Group AG | ADD | $455.4K |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | TRIM | $312.9K |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | $246.7K |
| JANE STREET GROUP, LLC | NEAR_EXIT | $126.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Sep 2024Price is below the lowest target. Median implies +79%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| May 20, 2024 | HC Wainwright & Co. REITERATE | Neutral |
| May 17, 2023 | Canaccord Genuity MAINTAIN | Hold |
| Jan 17, 2023 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Jan 12, 2023 | Canaccord Genuity DOWNGRADE | Hold |
| May 16, 2022 | Aegis Capital MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kidron Miriam Chief Scientific Officer Nov 12, 2026 | AWARD | 242,000 sh |
Aghion Daniel Director Nov 12, 2026 | AWARD | 72,780 sh |
Kidron Miriam Chief Scientific Officer Nov 12, 2026 | AWARD | 357,000 sh |
Gabay Avraham Chief Financial Officer Nov 12, 2026 | AWARD | 357,000 sh |
Gabay Avraham Chief Financial Officer Nov 12, 2026 | AWARD | 242,000 sh |
Hexter Joshua COO & CBO Nov 12, 2026 | AWARD | 357,000 sh |
Hexter Joshua COO & CBO Nov 12, 2026 | AWARD | 242,000 sh |
KIDRON NADAV President and CEO Nov 12, 2026 | AWARD | 629,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.37 | $0.37–$0.37 | -19.6% | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | $4.47 | $4.47–$4.47 | +93.5% | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
4 filings · 0 bullish · 0 bearish · 1 mixed · 3 neutral- NEUTRAL SC 13G/ANov 13, 2026
Aquamarine Financial (Cayman) Ltd filed an amended Schedule 13G disclosing a 6.38% passive stake…
Aquamarine is a new 5%+ passive holder. Monitor for any future conversion to 13D (activist intent) or further stake changes. The passive certification limits near-term activist risk.
- NEUTRAL CLUSTEROct 2, 2026
Two C-suite insiders at Oramed Pharmaceuticals sold a combined $226K in open-market sales on the…
The sales are small relative to market cap and occurred on the same day at the same price, suggesting coordinated liquidity needs or tax planning rather than negative information. Monitor next 10-Q…
- NEUTRAL CLUSTERJul 2, 2026
COO/CBO Joshua Hexter and CFO Avraham Gabay collectively sold $942K in open-market shares on July…
Insider selling at this scale is notable but not alarming for a $189M biotech. Watch for any upcoming corporate events (e.g., clinical data, partnership announcements) that may have motivated the…
- MIXED 8-KJun 30, 2026
Oramed Pharmaceuticals extended payment obligations from Scilex Holding Company, covering…
Monitor Scilex's ability to meet the July 31 and September 30 payment deadlines. Stock settlement alternative introduces dilution risk for Scilex but provides Oramed with a recovery path. The bylaw…
All ORMP filing & press-release reports (4)
- SC 13G/A reportNov 13, 2026
- CLUSTER reportOct 2, 2026
- CLUSTER reportJul 2, 2026
- 8-K reportJun 30, 2026